Article Information
History
- January 27, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Oliver Stirrup, PhD*,2,
- Maria Krutikov, MRCP*,1,#,
- Gokhan Tut, PhD*,4,
- Tom Palmer, MSc2,
- David Bone4,
- Rachel Bruton, PhD4,
- Chris Fuller, MSc1,
- Borscha Azmi, MSc1,
- Tara Lancaster, PhD4,
- Panagiota Sylla, MSc4,
- Nayandeep Kaur, MSc4,
- Eliska Spalkova, MSc4,
- Christopher Bentley, BSc4,
- Umayr Amin, MSc4,
- Azar Jadir, MSc4,
- Samuel Hulme, MSc4,
- Rebecca Giddings, DFPH1,
- Hadjer Nacer-Laidi, PhD1,
- Verity Baynton6,
- Aidan Irwin-Singer, MA6,
- Andrew Hayward, MD3,5,
- Paul Moss, PhD4,
- Andrew Copas, PhD2 and
- Laura Shallcross, PhD1
- 1UCL Institute of Health Informatics, London, UK
- 2UCL Institute for Global Health, London, UK
- 3UCL Institute of Epidemiology & Health Care
- 4Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
- 5Health Data Research UK
- 6Department of Health and Social Care, London, UK
- ↵#Correspondence to:
Dr Maria Krutikov, UCL Institute of Health Informatics, 222 Euston Rd, London NW1 2DA; m.krutikov{at}ucl.ac.uk
↵* authors contributed equally
Posted January 27, 2022.
SARS-CoV-2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 in residents of long-term care facilities in England (VIVALDI)
